Identification

Name
Cimetidine
Accession Number
DB00501  (APRD00568)
Type
Small Molecule
Groups
Approved, Investigational
Description

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. [PubChem]

Structure
Thumb
Synonyms
  • 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
  • 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
  • Cimetag
  • Cimetidin
  • Cimetidina
  • Cimétidine
  • Cimetidinum
  • N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
  • N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
  • Tagamet hb 200
  • Ulcerfen
External IDs
NSC-335308 / SKF 92334 / SKF-92334
Product Ingredients
IngredientUNIICASInChI Key
Cimetidine HydrochlorideWF1049167370059-30-2QJHCNBWLPSXHBL-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Cimetidine Tab 200mgTablet200 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo Cimetidine Tab 300mgTablet300 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo Cimetidine Tab 400mgTablet400 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo Cimetidine Tab 600mgTablet600 mgOralApotex Corporation1983-12-31Not applicableCanada
Cimetidine 200 Tab 200mgTablet200 mgOralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 300mgTablet300 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Cimetidine Tab 400mgTablet400 mgOralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 600mgTablet600 mgOralPro Doc Limitee1984-12-312012-07-23Canada
Peptol Tab 200mgTablet200 mgOralCarter Horner Corp.1981-12-312004-07-09Canada
Peptol Tab 300mgTablet300 mgOralCarter Horner Corp.1981-12-312004-07-09Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cimetidine Oral SolutionLiquid300 mgOralApotex Corporation2001-01-05Not applicableCanada
Apo-cimetidine Tab 800mgTablet800 mgOralApotex Corporation1988-12-31Not applicableCanada
CimetidineTablet, film coated300 mg/1OralRemedy Repack2014-08-01Not applicableUs
CimetidineTablet, film coated800 mg/1OralPhysicians Total Care, Inc.1994-05-23Not applicableUs
CimetidineTablet, film coated400 mg/1OralTeva2004-02-02Not applicableUs
CimetidineTablet, film coated300 mg/1OralCarilion Materials Management2003-11-24Not applicableUs
CimetidineTablet, film coated400 mg/1OralDispensing Solutions, Inc.2010-05-26Not applicableUs
CimetidineTablet, film coated300 mg/1OralBlenheim Pharmacal, Inc.2014-01-14Not applicableUs
CimetidineTablet, film coated400 mg/1OralAidarex Pharmaceuticals LLC2004-02-02Not applicableUs
CimetidineTablet, film coated800 mg/1OralMylan Pharmaceuticals1994-05-17Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet200 mg/1OralKroger2015-10-21Not applicableUs
Acid ReducerTablet200 mg/1OralRite Aid2005-07-082017-11-14Us
Cimetidine Acid ReducerTablet200 mg/1OralWalgreen2001-03-27Not applicableUs
DG Health Heartburn ReliefTablet200 mg/1OralDolgencorp2010-03-022017-11-18Us
Equaline Acid ReducerTablet200 mg/1OralSupervalu2004-09-152017-12-22Us
Equate CimetidineTablet200 mg/1OralWalmart Stores2006-09-27Not applicableUs
Gaviscon All-nightTablet100 mgOralGlaxosmithkline IncNot applicableNot applicableCanada
Gaviscon PreventTablet100 mgOralGlaxosmithkline Inc1998-08-172002-07-31Canada
Gaviscon Prevent Extra StrengthTablet200 mgOralGlaxosmithkline IncNot applicableNot applicableCanada
Good Neighbor Pharmacy Heartburn ReliefTablet200 mg/1OralAmerisource Bergen2000-01-05Not applicableUs
International/Other Brands
Cimetag (Julphar) / Tagamet HB200 (GlaxoSmithKline) / Ulcedine / Ulcerfen (Finadiet) / Ulcimet (Farmasa)
Categories
UNII
80061L1WGD
CAS number
51481-61-9
Weight
Average: 252.339
Monoisotopic: 252.115715232
Chemical Formula
C10H16N6S
InChI Key
AQIXAKUUQRKLND-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
IUPAC Name
(Z)-1-cyano-2-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
SMILES
C\N=C(\NCCSCC1=C(C)NC=N1)NC#N

Pharmacology

Indication

For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.

Associated Conditions
Pharmacodynamics

Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.

Mechanism of action

Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Human
Absorption

Rapid 60-70%

Volume of distribution
Not Available
Protein binding

15-20%

Metabolism

Hepatic

Route of elimination

The principal route of excretion of cimetidine is the urine.

Half life

2 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cimetidine Action PathwayDrug action
Cimetidine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinCimetidine may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinCimetidine may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Cimetidine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Experimental, Illicit
4-hydroxycoumarinCimetidine may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Cimetidine.Investigational
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Cimetidine.Experimental
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Cimetidine.Experimental
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Cimetidine.Experimental
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Cimetidine.Approved
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Cimetidine.Experimental
9-MethylguanineThe metabolism of 9-Methylguanine can be decreased when combined with Cimetidine.Experimental
AbemaciclibThe serum concentration of Cimetidine can be increased when it is combined with Abemaciclib.Approved, Investigational
AcebutololThe metabolism of Acebutolol can be decreased when combined with Cimetidine.Approved, Investigational
AcefyllineThe metabolism of Acefylline can be decreased when combined with Cimetidine.Experimental
AcenocoumarolCimetidine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Cimetidine can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe serum concentration of Acetohexamide can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
AcyclovirThe metabolism of Acyclovir can be decreased when combined with Cimetidine.Approved
AfatinibThe serum concentration of Cimetidine can be increased when it is combined with Afatinib.Approved
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Cimetidine.Experimental, Investigational
AlaproclateThe metabolism of Alaproclate can be decreased when combined with Cimetidine.Experimental
AlbendazoleThe serum concentration of Cimetidine can be increased when it is combined with Albendazole.Approved, Vet Approved
AlectinibThe serum concentration of Cimetidine can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Cimetidine.Approved, Illicit
AlprenololThe metabolism of Alprenolol can be decreased when combined with Cimetidine.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Aluminium clofibrate.Experimental
AmantadineThe serum concentration of Cimetidine can be increased when it is combined with Amantadine.Approved
AmilorideThe serum concentration of Cimetidine can be increased when it is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Cimetidine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cimetidine.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.Approved
AmodiaquineThe serum concentration of Cimetidine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Cimetidine can be increased when it is combined with Amoxapine.Approved
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Illicit, Investigational
AmsacrineThe serum concentration of Cimetidine can be increased when it is combined with Amsacrine.Approved, Investigational
AnisodamineThe metabolism of Anisodamine can be decreased when combined with Cimetidine.Investigational
AnnamycinThe serum concentration of Cimetidine can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Cimetidine can be decreased when it is combined with Apalutamide.Approved, Investigational
AranidipineThe serum concentration of Aranidipine can be increased when it is combined with Cimetidine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.Approved, Investigational
ArotinololThe metabolism of Arotinolol can be decreased when combined with Cimetidine.Investigational
AstemizoleThe serum concentration of Cimetidine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
AtazanavirCimetidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtenololThe metabolism of Atenolol can be decreased when combined with Cimetidine.Approved
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Cimetidine.Approved
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Cimetidine.Approved
AzelastineThe serum concentration of Cimetidine can be increased when it is combined with Azelastine.Approved
AzelnidipineThe serum concentration of Azelnidipine can be increased when it is combined with Cimetidine.Approved, Investigational
AzithromycinThe serum concentration of Cimetidine can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Cimetidine can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Cimetidine can be increased when it is combined with Bafilomycin B1.Experimental
BamifyllineThe metabolism of Bamifylline can be decreased when combined with Cimetidine.Experimental
BaricitinibThe serum concentration of Cimetidine can be increased when it is combined with Baricitinib.Approved, Investigational
BefunololThe metabolism of Befunolol can be decreased when combined with Cimetidine.Experimental
BencyclaneThe serum concentration of Bencyclane can be increased when it is combined with Cimetidine.Experimental
BenidipineThe serum concentration of Benidipine can be increased when it is combined with Cimetidine.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Illicit
BenzquinamideThe serum concentration of Cimetidine can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Cimetidine can be increased when it is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineCimetidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cimetidine.Approved, Investigational
BetaxololThe metabolism of Betaxolol can be decreased when combined with Cimetidine.Approved, Investigational
BevantololThe metabolism of Bevantolol can be decreased when combined with Cimetidine.Approved
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Bezafibrate.Approved, Investigational
BicalutamideThe serum concentration of Cimetidine can be increased when it is combined with Bicalutamide.Approved
BioallethrinThe serum concentration of Bioallethrin can be increased when it is combined with Cimetidine.Approved, Experimental
Biricodar dicitrateThe serum concentration of Cimetidine can be increased when it is combined with Biricodar dicitrate.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cimetidine.Approved
BoceprevirThe serum concentration of Cimetidine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololThe metabolism of Bopindolol can be decreased when combined with Cimetidine.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cimetidine.Approved
Brefeldin AThe serum concentration of Cimetidine can be increased when it is combined with Brefeldin A.Experimental
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Cimetidine.Approved, Illicit, Investigational
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Cimetidine.Approved, Investigational
BromotheophyllineThe metabolism of Bromotheophylline can be decreased when combined with Cimetidine.Approved
BucindololThe metabolism of Bucindolol can be decreased when combined with Cimetidine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Cimetidine.Experimental, Investigational
BufyllineThe metabolism of Bufylline can be decreased when combined with Cimetidine.Experimental
BupranololThe metabolism of Bupranolol can be decreased when combined with Cimetidine.Approved
BuprenorphineThe serum concentration of Cimetidine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Cimetidine can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Cimetidine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cimetidine can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Cimetidine.Approved
CafedrineThe metabolism of Cafedrine can be decreased when combined with Cimetidine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Cimetidine.Approved
CanagliflozinThe serum concentration of Cimetidine can be increased when it is combined with Canagliflozin.Approved
CapecitabineThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Cimetidine.Approved, Investigational
Capromab pendetideCimetidine may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Cimetidine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.Approved, Investigational
CarboxyamidotriazoleThe serum concentration of Carboxyamidotriazole can be increased when it is combined with Cimetidine.Investigational
CarbutamideThe serum concentration of Carbutamide can be increased when it is combined with Cimetidine.Experimental
CarmustineCimetidine may increase the myelosuppressive activities of Carmustine.Approved, Investigational
CaroverineThe serum concentration of Caroverine can be increased when it is combined with Cimetidine.Experimental
CarteololThe metabolism of Carteolol can be decreased when combined with Cimetidine.Approved
CefditorenCimetidine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CefoperazoneThe serum concentration of Cimetidine can be increased when it is combined with Cefoperazone.Approved, Investigational
CefpodoximeCimetidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CeftriaxoneThe serum concentration of Cimetidine can be increased when it is combined with Ceftriaxone.Approved
CefuroximeCimetidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CeliprololThe metabolism of Celiprolol can be decreased when combined with Cimetidine.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cimetidine.Approved, Withdrawn
ChloroformThe serum concentration of Cimetidine can be increased when it is combined with Chloroform.Vet Approved
ChlorphenamineThe serum concentration of Cimetidine can be increased when it is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Cimetidine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Cimetidine can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.Approved, Investigational
ChlorprothixeneThe serum concentration of Cimetidine can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholineThe serum concentration of Choline can be increased when it is combined with Cimetidine.Approved, Nutraceutical
Choline C 11Cimetidine may decrease effectiveness of Choline C 11 as a diagnostic agent.Approved, Investigational
Choline salicylateThe serum concentration of Choline salicylate can be increased when it is combined with Cimetidine.Approved, Nutraceutical
CilnidipineThe serum concentration of Cilnidipine can be increased when it is combined with Cimetidine.Approved, Investigational
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Cimetidine.Approved, Investigational
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Ciprofibrate.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Cimetidine.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Cimetidine.Approved
ClarithromycinThe serum concentration of Cimetidine can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClofazimineThe serum concentration of Cimetidine can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Clofibride.Experimental
ClomipramineThe serum concentration of Cimetidine can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
CloranololThe metabolism of Cloranolol can be decreased when combined with Cimetidine.Experimental
ClorindioneCimetidine may increase the anticoagulant activities of Clorindione.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cimetidine.Approved
CobicistatThe serum concentration of Cimetidine can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Cimetidine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cimetidine.Approved, Illicit
ColchicineThe serum concentration of Cimetidine can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Cimetidine can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Cimetidine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Cimetidine can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Cimetidine can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe serum concentration of Cyclandelate can be increased when it is combined with Cimetidine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.Approved
CyclosporineThe serum concentration of Cimetidine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CysteamineCimetidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
D-LevofloxacinThe serum concentration of Cimetidine can be increased when it is combined with D-Levofloxacin.Experimental
DabrafenibCimetidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaclatasvirThe serum concentration of Cimetidine can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Cimetidine can be increased when it is combined with Dactinomycin.Approved, Investigational
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Cimetidine.Approved
DapoxetineThe metabolism of Dapoxetine can be decreased when combined with Cimetidine.Investigational
DarodipineThe serum concentration of Darodipine can be increased when it is combined with Cimetidine.Experimental
DasatinibCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Cimetidine can be increased when it is combined with Daunorubicin.Approved
DelavirdineCimetidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesipramineThe serum concentration of Cimetidine can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Cimetidine can be increased when it is combined with Desmethylsertraline.Experimental
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Cimetidine.Approved, Investigational
Dexchlorpheniramine maleateThe serum concentration of Cimetidine can be increased when it is combined with Dexchlorpheniramine maleate.Approved
DexmethylphenidateThe therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Cimetidine.Approved, Investigational
DexniguldipineThe serum concentration of Dexniguldipine can be increased when it is combined with Cimetidine.Experimental
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cimetidine.Approved
DexverapamilThe serum concentration of Dexverapamil can be increased when it is combined with Cimetidine.Experimental
DicoumarolCimetidine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe serum concentration of Cimetidine can be increased when it is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Cimetidine.Approved, Illicit
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Cimetidine.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Cimetidine.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Cimetidine.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Cimetidine.Approved, Investigational
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cimetidine.Approved, Investigational
DinoprostoneThe serum concentration of Cimetidine can be increased when it is combined with Dinoprostone.Approved
DiphenadioneCimetidine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe serum concentration of Cimetidine can be increased when it is combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe serum concentration of Cimetidine can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe serum concentration of Cimetidine can be increased when it is combined with Disopyramide.Approved
DofequidarThe serum concentration of Cimetidine can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideCimetidine may decrease the excretion rate of Dofetilide which could result in a higher serum level.Approved, Investigational
DolutegravirThe serum concentration of Cimetidine can be increased when it is combined with Dolutegravir.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Cimetidine.Approved
DosulepinThe metabolism of Dosulepin can be decreased when combined with Cimetidine.Approved
DotarizineThe serum concentration of Dotarizine can be increased when it is combined with Cimetidine.Investigational
DovitinibThe serum concentration of Cimetidine can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Cimetidine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Cimetidine can be increased when it is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Cimetidine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cimetidine.Approved, Investigational
DronabinolThe serum concentration of Cimetidine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Cimetidine can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Cimetidine.Approved
EconazoleThe serum concentration of Cimetidine can be increased when it is combined with Econazole.Approved
EfonidipineThe serum concentration of Efonidipine can be increased when it is combined with Cimetidine.Approved, Investigational
ElacridarThe serum concentration of Cimetidine can be increased when it is combined with Elacridar.Investigational
ElagolixThe metabolism of Elagolix can be decreased when combined with Cimetidine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cimetidine.Approved
EmopamilThe serum concentration of Emopamil can be increased when it is combined with Cimetidine.Experimental
EnasidenibThe serum concentration of Cimetidine can be increased when it is combined with Enasidenib.Approved, Investigational
EntecavirThe metabolism of Entecavir can be decreased when combined with Cimetidine.Approved, Investigational
EnzalutamideThe serum concentration of Cimetidine can be increased when it is combined with Enzalutamide.Approved
EpanololThe metabolism of Epanolol can be decreased when combined with Cimetidine.Experimental
EperisoneThe serum concentration of Eperisone can be increased when it is combined with Cimetidine.Approved, Investigational
EpinephrineThe serum concentration of Epinephrine can be increased when it is combined with Cimetidine.Approved, Vet Approved
EpirubicinThe serum concentration of Epirubicin can be increased when it is combined with Cimetidine.Approved
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Cimetidine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Cimetidine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Cimetidine.Approved
ErlotinibCimetidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ErythromycinThe serum concentration of Cimetidine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe metabolism of Esatenolol can be decreased when combined with Cimetidine.Experimental
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.Approved, Investigational
EsmololThe metabolism of Esmolol can be decreased when combined with Cimetidine.Approved
EsomeprazoleThe serum concentration of Cimetidine can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Cimetidine can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Cimetidine can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Cimetidine can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Cimetidine can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Cimetidine can be increased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Cimetidine can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Cimetidine can be increased when it is combined with Estramustine.Approved, Investigational
EtamiphyllineThe metabolism of Etamiphylline can be decreased when combined with Cimetidine.Experimental
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Cimetidine.Approved
Ethyl biscoumacetateCimetidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Etofibrate.Approved
EtoposideThe serum concentration of Cimetidine can be increased when it is combined with Etoposide.Approved
FamotidineThe serum concentration of Cimetidine can be increased when it is combined with Famotidine.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.Approved, Investigational
FendilineThe serum concentration of Fendiline can be increased when it is combined with Cimetidine.Withdrawn
FenethyllineThe metabolism of Fenethylline can be decreased when combined with Cimetidine.Approved
FenofibrateThe serum concentration of Cimetidine can be increased when it is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Fenofibric acid.Approved
FentanylThe serum concentration of Cimetidine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric ammonium citrateCimetidine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseCimetidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationCimetidine can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideCimetidine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideCimetidine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateCimetidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateCimetidine can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateCimetidine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateCimetidine can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideCimetidine can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateCimetidine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateCimetidine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateCimetidine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateCimetidine can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesCimetidine can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilCimetidine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolCimetidine can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.Approved
Fish oilThe serum concentration of Fish oil can be increased when it is combined with Cimetidine.Approved, Nutraceutical
FlecainideThe metabolism of Flecainide can be decreased when combined with Cimetidine.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cimetidine.Approved, Investigational
FloxuridineThe serum concentration of the active metabolites of Floxuridine can be increased when Floxuridine is used in combination with Cimetidine.Approved
FluconazoleThe serum concentration of Cimetidine can be increased when it is combined with Fluconazole.Approved, Investigational
FluindioneCimetidine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Cimetidine.Approved
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Cimetidine.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.Approved, Vet Approved
FlupentixolThe serum concentration of Cimetidine can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Cimetidine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Cimetidine can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe serum concentration of Fluspirilene can be increased when it is combined with Cimetidine.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Cimetidine.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.Approved, Investigational
FosamprenavirCimetidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Fosphenytoin.Approved, Investigational
FurafyllineThe metabolism of Furafylline can be decreased when combined with Cimetidine.Experimental
FurosemideThe excretion of Cimetidine can be decreased when combined with Furosemide.Approved, Vet Approved
GabapentinThe serum concentration of Gabapentin can be increased when it is combined with Cimetidine.Approved, Investigational
GallopamilThe serum concentration of Gallopamil can be increased when it is combined with Cimetidine.Investigational
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Cimetidine.Approved, Investigational
GefitinibCimetidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Cimetidine can be increased when it is combined with Genistein.Investigational
GepefrineGepefrine may decrease the sedative and stimulatory activities of Cimetidine.Experimental
GlecaprevirThe serum concentration of Cimetidine can be increased when it is combined with Glecaprevir.Approved, Investigational
GleptoferronCimetidine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlibornurideThe serum concentration of Glibornuride can be increased when it is combined with Cimetidine.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Cimetidine.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Cimetidine.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Cimetidine.Approved, Investigational
GliquidoneThe serum concentration of Gliquidone can be increased when it is combined with Cimetidine.Approved, Investigational
GlisoxepideThe serum concentration of Glisoxepide can be increased when it is combined with Cimetidine.Investigational
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Cimetidine.Approved
GlycerinThe serum concentration of Cimetidine can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Cimetidine can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Cimetidine can be increased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanidineThe serum concentration of Cimetidine can be increased when it is combined with Guanidine.Approved
GuanineThe metabolism of Guanine can be decreased when combined with Cimetidine.Experimental
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Cimetidine.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Cimetidine.Approved, Investigational
HM-30181The serum concentration of Cimetidine can be increased when it is combined with HM-30181.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.Approved, Investigational
HycanthoneThe serum concentration of Cimetidine can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Cimetidine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Approved
HydroxychloroquineThe serum concentration of Cimetidine can be increased when it is combined with Hydroxychloroquine.Approved
HypoxanthineThe metabolism of Hypoxanthine can be decreased when combined with Cimetidine.Experimental
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Cimetidine.Approved
IbuprofenThe serum concentration of Cimetidine can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe serum concentration of Cimetidine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Cimetidine can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Cimetidine can be increased when it is combined with Imipramine.Approved
IndalpineThe metabolism of Indalpine can be decreased when combined with Cimetidine.Investigational, Withdrawn
IndenololThe metabolism of Indenolol can be decreased when combined with Cimetidine.Withdrawn
IndinavirCimetidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndomethacinThe serum concentration of Cimetidine can be increased when it is combined with Indomethacin.Approved, Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Cimetidine.Approved
IronCimetidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Cimetidine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateCimetidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe serum concentration of Cimetidine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Cimetidine.Approved, Investigational
ItraconazoleCimetidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IvacaftorThe serum concentration of Cimetidine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Cimetidine can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Cimetidine can be increased when it is combined with Ivosidenib.Approved, Investigational
KetoconazoleCimetidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Cimetidine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cimetidine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.Approved, Investigational
LandiololThe metabolism of Landiolol can be decreased when combined with Cimetidine.Investigational
LaniquidarThe serum concentration of Cimetidine can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Cimetidine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Cimetidine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirCimetidine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LenvatinibThe serum concentration of Cimetidine can be increased when it is combined with Lenvatinib.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.Approved, Investigational
LetermovirThe serum concentration of Cimetidine can be increased when it is combined with Letermovir.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cimetidine.Approved, Investigational
LevobetaxololThe metabolism of Levobetaxolol can be decreased when combined with Cimetidine.Approved, Investigational
LevobunololThe metabolism of Levobunolol can be decreased when combined with Cimetidine.Approved
LevofloxacinThe serum concentration of Cimetidine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cimetidine.Approved, Investigational
LidocaineThe serum concentration of Cimetidine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe serum concentration of Lidoflazine can be increased when it is combined with Cimetidine.Experimental
LinagliptinThe serum concentration of Cimetidine can be increased when it is combined with Linagliptin.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Investigational
LisofyllineThe metabolism of Lisofylline can be decreased when combined with Cimetidine.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Cimetidine.Approved, Investigational
LobucavirThe metabolism of Lobucavir can be decreased when combined with Cimetidine.Investigational
LomerizineThe serum concentration of Lomerizine can be increased when it is combined with Cimetidine.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cimetidine.Approved, Investigational
LonafarnibThe serum concentration of Cimetidine can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cimetidine.Approved
LopinavirThe serum concentration of Cimetidine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Cimetidine can be increased when it is combined with Loratadine.Approved, Investigational
LosartanThe serum concentration of Cimetidine can be increased when it is combined with Losartan.Approved
LoxapineThe serum concentration of Cimetidine can be increased when it is combined with Loxapine.Approved
LumacaftorThe serum concentration of Cimetidine can be decreased when it is combined with Lumacaftor.Approved
LusutrombopagThe serum concentration of Cimetidine can be increased when it is combined with Lusutrombopag.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Cimetidine.Illicit, Investigational, Withdrawn
Magnesium sulfateThe serum concentration of Magnesium sulfate can be increased when it is combined with Cimetidine.Approved, Investigational, Vet Approved
ManidipineThe serum concentration of Manidipine can be increased when it is combined with Cimetidine.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Cimetidine.Approved, Vet Approved
MefloquineThe serum concentration of Cimetidine can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Cimetidine can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Cimetidine.Approved, Investigational
MentholThe serum concentration of Menthol can be increased when it is combined with Cimetidine.Approved
MephedroneMephedrone may decrease the sedative and stimulatory activities of Cimetidine.Investigational
MephentermineMephentermine may decrease the sedative and stimulatory activities of Cimetidine.Approved
MepindololThe metabolism of Mepindolol can be decreased when combined with Cimetidine.Experimental
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Cimetidine.Approved
MetahexamideThe serum concentration of Metahexamide can be increased when it is combined with Cimetidine.Experimental
MetergolineThe metabolism of Metergoline can be decreased when combined with Cimetidine.Experimental
MetforminThe serum concentration of Metformin can be increased when it is combined with Cimetidine.Approved
MethadoneThe serum concentration of Cimetidine can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Cimetidine.Experimental
MethsuximideThe serum concentration of Methsuximide can be increased when it is combined with Cimetidine.Approved
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Cimetidine.Approved
MethylphenidateThe therapeutic efficacy of Methylphenidate can be decreased when used in combination with Cimetidine.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Cimetidine.Approved
MetipranololThe metabolism of Metipranolol can be decreased when combined with Cimetidine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cimetidine.Approved, Investigational
MetronidazoleThe serum concentration of Cimetidine can be increased when it is combined with Metronidazole.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Cimetidine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cimetidine.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Cimetidine.Investigational, Withdrawn
MiconazoleThe serum concentration of Cimetidine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Cimetidine can be increased when it is combined with Midazolam.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Cimetidine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Cimetidine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe metabolism of Milnacipran can be decreased when combined with Cimetidine.Approved, Investigational
MitotaneThe serum concentration of Cimetidine can be increased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Cimetidine can be increased when it is combined with Mitoxantrone.Approved, Investigational
MMDAMMDA may decrease the sedative and stimulatory activities of Cimetidine.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cimetidine.Approved, Investigational
MonensinThe serum concentration of Cimetidine can be increased when it is combined with Monensin.Vet Approved
NadololThe metabolism of Nadolol can be decreased when combined with Cimetidine.Approved
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Cimetidine.Approved, Investigational
NaftopidilThe serum concentration of Naftopidil can be increased when it is combined with Cimetidine.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Cimetidine.Approved, Withdrawn
NelfinavirCimetidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NeratinibThe serum concentration of Cimetidine can be increased when it is combined with Neratinib.Approved, Investigational
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Cimetidine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Cimetidine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cimetidine.Approved
NigericinThe serum concentration of Cimetidine can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Niguldipine can be increased when it is combined with Cimetidine.Experimental
NilotinibCimetidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be increased when it is combined with Cimetidine.Experimental
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Cimetidine.Approved, Investigational
NimesulideThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cimetidine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cimetidine.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.Approved, Investigational
NitroprussideCimetidine can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NorepinephrineThe serum concentration of Norepinephrine can be increased when it is combined with Cimetidine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.Approved
NylidrinThe serum concentration of Nylidrin can be increased when it is combined with Cimetidine.Approved
OmeprazoleThe serum concentration of Cimetidine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cimetidine.Approved
ONT-093The serum concentration of Cimetidine can be increased when it is combined with ONT-093.Investigational
OpipramolThe metabolism of Opipramol can be decreased when combined with Cimetidine.Investigational
OtiloniumThe serum concentration of Otilonium can be increased when it is combined with Cimetidine.Experimental, Investigational
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Cimetidine.Approved, Investigational
OxprenololThe serum concentration of Cimetidine can be increased when it is combined with Oxprenolol.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Cimetidine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Cimetidine.Approved, Illicit, Investigational
PaclitaxelThe serum concentration of Cimetidine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe serum concentration of Cimetidine can be increased when it is combined with Paliperidone.Approved
PantoprazoleThe serum concentration of Cimetidine can be increased when it is combined with Pantoprazole.Approved
ParitaprevirThe serum concentration of Cimetidine can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.Approved, Investigational
PazopanibCimetidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeldesineThe metabolism of Peldesine can be decreased when combined with Cimetidine.Experimental, Investigational
PemetrexedThe metabolism of Pemetrexed can be decreased when combined with Cimetidine.Approved, Investigational
PenbutololThe metabolism of Penbutolol can be decreased when combined with Cimetidine.Approved, Investigational
PenciclovirThe metabolism of Penciclovir can be decreased when combined with Cimetidine.Approved
PenfluridolThe serum concentration of Penfluridol can be increased when it is combined with Cimetidine.Experimental
PentazocineThe serum concentration of Cimetidine can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentifyllineThe metabolism of Pentifylline can be decreased when combined with Cimetidine.Experimental
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Cimetidine.Approved, Investigational
PerflubutaneCimetidine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Cimetidine.Approved, Investigational, Vet Approved, Withdrawn
PhenforminThe serum concentration of Cimetidine can be increased when it is combined with Phenformin.Approved, Investigational, Withdrawn
PhenindioneCimetidine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenoxybenzamineThe serum concentration of Cimetidine can be increased when it is combined with Phenoxybenzamine.Approved
PhenprocoumonCimetidine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Cimetidine can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimagedineThe serum concentration of Cimetidine can be increased when it is combined with Pimagedine.Investigational
PimozideThe serum concentration of Cimetidine can be increased when it is combined with Pimozide.Approved
PinaveriumThe serum concentration of Pinaverium can be increased when it is combined with Cimetidine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Cimetidine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cimetidine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Cimetidine.Approved, Investigational
PonatinibThe serum concentration of Cimetidine can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleCimetidine can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PractololThe metabolism of Practolol can be decreased when combined with Cimetidine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cimetidine.Approved
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Cimetidine.Approved, Investigational, Vet Approved
PrazosinThe serum concentration of Cimetidine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Cimetidine can be increased when it is combined with Prednisone.Approved, Vet Approved
PrenylamineThe serum concentration of Prenylamine can be increased when it is combined with Cimetidine.Withdrawn
PrimaquineThe serum concentration of Cimetidine can be increased when it is combined with Primaquine.Approved
ProbenecidThe serum concentration of Cimetidine can be increased when it is combined with Probenecid.Approved, Investigational
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Cimetidine.Approved
ProgesteroneThe serum concentration of Cimetidine can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Cimetidine can be increased when it is combined with Promethazine.Approved, Investigational
PropentofyllineThe metabolism of Propentofylline can be decreased when combined with Cimetidine.Investigational
PropofolThe serum concentration of Cimetidine can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Cimetidine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Cimetidine can be increased when it is combined with Protriptyline.Approved
ProxyphyllineThe metabolism of Proxyphylline can be decreased when combined with Cimetidine.Experimental
Prussian blueCimetidine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Cimetidine.Approved
QuercetinThe serum concentration of Cimetidine can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Cimetidine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cimetidine.Approved, Investigational
QuinineThe serum concentration of Quinine can be increased when it is combined with Cimetidine.Approved
RanitidineThe serum concentration of Cimetidine can be increased when it is combined with Ranitidine.Approved
ReboxetineThe serum concentration of Cimetidine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Cimetidine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Cimetidine can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Cimetidine can be increased when it is combined with Reversin 121.Experimental
RifampicinThe serum concentration of Cimetidine can be increased when it is combined with Rifampicin.Approved
RilpivirineCimetidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateCimetidine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Cimetidine.Approved, Investigational
RitanserinThe metabolism of Ritanserin can be decreased when combined with Cimetidine.Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Cimetidine.Investigational
RitonavirThe serum concentration of Cimetidine can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Cimetidine.Approved
RolapitantThe serum concentration of Cimetidine can be increased when it is combined with Rolapitant.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Ronifibrate.Experimental
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cimetidine.Approved
RucaparibThe serum concentration of Cimetidine can be increased when it is combined with Rucaparib.Approved, Investigational
SalinomycinThe serum concentration of Cimetidine can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirCimetidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
SeletracetamThe serum concentration of Seletracetam can be increased when it is combined with Cimetidine.Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Cimetidine.Approved
SimeprevirThe serum concentration of Cimetidine can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Simfibrate.Experimental
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cimetidine.Approved
Sodium feredetateCimetidine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SorafenibThe serum concentration of Cimetidine can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe metabolism of Sotalol can be decreased when combined with Cimetidine.Approved
StaurosporineThe serum concentration of Cimetidine can be increased when it is combined with Staurosporine.Experimental
SunitinibThe serum concentration of Cimetidine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantThe serum concentration of Cimetidine can be increased when it is combined with Suvorexant.Approved, Investigational
TacrolimusThe serum concentration of Cimetidine can be increased when it is combined with Tacrolimus.Approved, Investigational
TafenoquineThe serum concentration of Cimetidine can be increased when it is combined with Tafenoquine.Approved, Investigational
TalinololThe metabolism of Talinolol can be decreased when combined with Cimetidine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cimetidine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.Approved, Investigational
TariquidarThe serum concentration of Cimetidine can be increased when it is combined with Tariquidar.Investigational
TegafurThe serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Cimetidine.Approved, Investigational
TelaprevirThe serum concentration of Cimetidine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelmisartanThe serum concentration of Cimetidine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Cimetidine can be increased when it is combined with Temsirolimus.Approved
TerfenadineThe serum concentration of Cimetidine can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Cimetidine.Experimental
TeriflunomideThe serum concentration of Cimetidine can be increased when it is combined with Teriflunomide.Approved
TerodilineThe serum concentration of Terodiline can be increased when it is combined with Cimetidine.Experimental
TertatololThe metabolism of Tertatolol can be decreased when combined with Cimetidine.Experimental
TesmilifeneThe serum concentration of Cimetidine can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Cimetidine can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Cimetidine can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Cimetidine can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Cimetidine can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe excretion of Tetracycline can be decreased when combined with Cimetidine.Approved, Vet Approved
TetraethylammoniumThe serum concentration of Tetraethylammonium can be increased when it is combined with Cimetidine.Experimental, Investigational
Tetraferric tricitrate decahydrateCimetidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrahydropalmatineThe serum concentration of Tetrahydropalmatine can be increased when it is combined with Cimetidine.Investigational
TetrandrineThe serum concentration of Tetrandrine can be increased when it is combined with Cimetidine.Experimental
TheobromineThe metabolism of Theobromine can be decreased when combined with Cimetidine.Approved, Investigational
TheodrenalineThe metabolism of Theodrenaline can be decreased when combined with Cimetidine.Investigational
ThiamineThe serum concentration of Cimetidine can be increased when it is combined with Thiamine.Approved, Investigational, Nutraceutical, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.Approved, Withdrawn
TicagrelorThe serum concentration of Cimetidine can be increased when it is combined with Ticagrelor.Approved
TimololThe metabolism of Timolol can be decreased when combined with Cimetidine.Approved
TioclomarolCimetidine may increase the anticoagulant activities of Tioclomarol.Experimental
TipifarnibThe serum concentration of Cimetidine can be increased when it is combined with Tipifarnib.Investigational
TipiracilThe serum concentration of Tipiracil can be increased when it is combined with Cimetidine.Approved, Investigational
TipranavirThe serum concentration of Cimetidine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Cimetidine.Approved, Investigational
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Cimetidine.Approved, Investigational
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Cimetidine.Approved, Investigational
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Cimetidine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cimetidine.Approved
ToremifeneThe serum concentration of Cimetidine can be increased when it is combined with Toremifene.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.Approved, Investigational
TranilastThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Cimetidine.Approved, Investigational
TrifluoperazineThe serum concentration of Cimetidine can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Cimetidine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimebutineThe serum concentration of Trimebutine can be increased when it is combined with Cimetidine.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Cimetidine.Approved
TrimethoprimThe serum concentration of Cimetidine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.Approved
TroleandomycinThe serum concentration of Cimetidine can be increased when it is combined with Troleandomycin.Approved
Uric AcidThe metabolism of Uric Acid can be decreased when combined with Cimetidine.Experimental, Investigational
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Cimetidine.Approved, Investigational
ValganciclovirThe metabolism of Valganciclovir can be decreased when combined with Cimetidine.Approved, Investigational
ValinomycinThe serum concentration of Cimetidine can be increased when it is combined with Valinomycin.Experimental
ValomaciclovirThe metabolism of Valomaciclovir can be decreased when combined with Cimetidine.Investigational
ValspodarThe serum concentration of Cimetidine can be increased when it is combined with Valspodar.Investigational
VareniclineCimetidine may decrease the excretion rate of Varenicline which could result in a higher serum level.Approved, Investigational
VelpatasvirThe serum concentration of Cimetidine can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Cimetidine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Cimetidine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.Approved
VinblastineThe serum concentration of Cimetidine can be increased when it is combined with Vinblastine.Approved
VinpocetineThe serum concentration of Vinpocetine can be increased when it is combined with Cimetidine.Investigational
VoacamineThe serum concentration of Cimetidine can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Cimetidine can be increased when it is combined with Vorapaxar.Approved
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cimetidine.Approved, Investigational
VoxilaprevirThe serum concentration of Cimetidine can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinCimetidine may increase the anticoagulant activities of Warfarin.Approved
WIN 55212-2The serum concentration of WIN 55212-2 can be increased when it is combined with Cimetidine.Experimental
XanthineThe metabolism of Xanthine can be decreased when combined with Cimetidine.Experimental
YohimbineThe serum concentration of Cimetidine can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cimetidine.Approved, Illicit, Investigational
ZiconotideThe serum concentration of Ziconotide can be increased when it is combined with Cimetidine.Approved
ZidovudineThe excretion of Zidovudine can be decreased when combined with Cimetidine.Approved
ZimelidineThe metabolism of Zimelidine can be decreased when combined with Cimetidine.Withdrawn
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Cimetidine.Approved, Investigational
ZomepiracThe serum concentration of Cimetidine can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Cimetidine.Approved, Investigational
ZosuquidarThe serum concentration of Cimetidine can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
  • Avoid alcohol.
  • Best effect when taken with food.
  • Limit caffeine intake.

References

Synthesis Reference

Saburo Uchikuga, Tomoyasu Tashiro, Yasuko Osawa, "Process for preparing the H.sub.2 -receptor antagonist cimetidine." U.S. Patent US4413129, issued March, 1972.

US4413129
General References
  1. Michnovicz JJ, Galbraith RA: Cimetidine inhibits catechol estrogen metabolism in women. Metabolism. 1991 Feb;40(2):170-4. [PubMed:1988774]
External Links
Human Metabolome Database
HMDB0014644
KEGG Drug
D00295
KEGG Compound
C06952
PubChem Compound
2756
PubChem Substance
46505360
ChemSpider
2654
BindingDB
22889
ChEBI
3699
ChEMBL
CHEMBL30
Therapeutic Targets Database
DAP000338
PharmGKB
PA449001
IUPHAR
1231
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cimetidine
ATC Codes
A02BA01 — CimetidineA02BA51 — Cimetidine, combinations
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (420 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherDrug-Drug Interaction (DDI) / Pharmacokinetics1
1CompletedOtherHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
1TerminatedNot AvailableGeneralized Anxiety Disorder (GAD)1
1Unknown StatusBasic ScienceHealthy Volunteers1
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentMelanoma (Skin) / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedPreventionPeptic ulcer haemorrhage1
3CompletedPreventionStress Ulcer Prophylaxis1
3CompletedPreventionUpper Gastrointestinal Hemorrhage1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Contract pharmacal corp
  • Dava pharmaceuticals inc
  • Endo pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • L perrigo co
  • Perrigo co
  • Pliva inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Teva parenteral medicines inc
  • Actavis mid atlantic llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Hi tech pharmacal co inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Central Texas Community Health Centers
  • Comprehensive Consultant Services Inc.
  • Darby Dental Supply Co. Inc.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline Inc.
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hi Tech Pharmacal Co. Inc.
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Lek Pharmaceuticals Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novex Pharma
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharma Pac LLC
  • Pharmaceutical Association
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Sandhills Packaging Inc.
  • Sanofi-Aventis Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
TabletOral200 mg
TabletOral300 mg
TabletOral600 mg
TabletOral400 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral800 mg/1
TabletOral200 mg/1
SolutionOral300 mg/5mL
TabletOral100 mg
SolutionIntramuscular; Intravenous150 mg
TabletOral400 mg
TabletOral800 mg
LiquidIntravenous6 mg
LiquidIntramuscular; Intravenous150 mg
LiquidOral300 mg
LiquidOral60 mg
Prices
Unit descriptionCostUnit
Cimetidine 800 mg tablet2.7USD tablet
Tagamet 400 mg tablet2.51USD tablet
Cimetidine 150 mg/ml vial1.67USD ml
Cimetidine powder1.48USD g
Cimetidine 400 mg tablet1.44USD tablet
Tagamet 300 mg tablet1.28USD tablet
Cimetidine 300 mg tablet0.93USD tablet
Cimetidine 200 mg tablet0.46USD tablet
Cimetidine HCl 300 mg/5ml Solution0.38USD ml
Tagamet hb 200 mg tablet0.37USD tablet
Apo-Cimetidine 800 mg Tablet0.27USD tablet
Mylan-Cimetidine 800 mg Tablet0.27USD tablet
Acid reducer 200 mg tablet0.21USD tablet
Apo-Cimetidine 600 mg Tablet0.18USD tablet
Mylan-Cimetidine 600 mg Tablet0.18USD tablet
Novo-Cimetine 600 mg Tablet0.18USD tablet
Nu-Cimet 600 mg Tablet0.18USD tablet
Apo-Cimetidine 400 mg Tablet0.14USD tablet
Mylan-Cimetidine 400 mg Tablet0.14USD tablet
Novo-Cimetine 400 mg Tablet0.14USD tablet
Nu-Cimet 400 mg Tablet0.14USD tablet
Apo-Cimetidine 200 mg Tablet0.09USD tablet
Apo-Cimetidine 300 mg Tablet0.09USD tablet
Mylan-Cimetidine 300 mg Tablet0.09USD tablet
Novo-Cimetine 300 mg Tablet0.09USD tablet
Nu-Cimet 300 mg Tablet0.09USD tablet
Heartburn relief 200 mg tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142 °CPhysProp
water solubility9380 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.40HANSCH,C ET AL. (1995)
logS-1.35ADME Research, USCD
Caco2 permeability-5.89ADME Research, USCD
pKa6.8TOMLINSON,E & HAFKENSCHEID,TL (1986)
Predicted Properties
PropertyValueSource
Water Solubility0.816 mg/mLALOGPS
logP0.44ALOGPS
logP-0.11ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.38ChemAxon
pKa (Strongest Basic)6.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.32 m3·mol-1ChemAxon
Polarizability27.47 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9855
Blood Brain Barrier-0.6782
Caco-2 permeable-0.6358
P-glycoprotein substrateSubstrate0.7887
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.7233
CYP450 2C9 substrateNon-substrate0.8048
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5795
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5773
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9575
Ames testNon AMES toxic0.837
CarcinogenicityNon-carcinogens0.9579
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7341 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7983
hERG inhibition (predictor II)Non-inhibitor0.8745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-002b-9510000000-36ce01132725fd5bf5d8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4j-5900000000-122f9dbdf583bbe3dee8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9300000000-39ee157d9e264867cfa4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9000000000-6e876a668444c8277412
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9000000000-85640be9b2799889fd02
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-9000000000-9b8d3eafde213bee6396
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4j-9000000000-b47e11697992a843f5e4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-9000000000-75ebe86c90f5ed341c57
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0aor-9000000000-d7302885bef7454b4db2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-b2f3ab1b5ae1e2f8f8bb
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-0930000000-dbae8348b5c999cc664d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052b-9600000000-8b4b94cd7303c9b9a0ef
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-9000000000-c23b62afdf4dff8c43db
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-9000000000-e477cd71a628f6adaf46
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052e-9000000000-61584ad991262d50a01b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0zfr-1980000000-84e04b032e6f422e5b6b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aos-2900000000-e8d9297512335ce612fb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052b-9800000000-7235208cf21d7ea1f7ad
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9300000000-4996f6630fe29fccd7d1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9100000000-a5e040b5d19e189571ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-d8853f62b77fc7f6ab01
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-a5bdbde532dc871c2dc3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-114j-9000000000-89e11e4ab1dbea690ecd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-1000-9000000000-2968f2af0b540684c21f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0090000000-b6ea3493555e798b637d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0aos-2910000000-c696b6aba5edd10fe848
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00kb-9700000000-6b130a82094066468edc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-9200000000-6f64d37f41bf3bddd538
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-9100000000-f23125855effae49cbd8
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0aor-0900000000-9d38315a88e4b11bc9e7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0pb9-2940000000-eb44b45cbe2d97c7791c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-9511000000-75fc9243ad1eb9c79cb4
1H NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as imidazoles. These are compounds containing an imidazole ring, which is an aromatic five-member ring with two nitrogen atoms at positions 1 and 3, and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Imidazoles
Alternative Parents
Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Imines / Hydrocarbon derivatives
Substituents
Imidazole / Heteroaromatic compound / Guanidine / Thioether / Carboximidamide / Sulfenyl compound / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound / Dialkylthioether / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, guanidines, aliphatic sulfide, nitrile (CHEBI:3699)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hernandez-Munoz R, Montiel-Ruiz C, Vazquez-Martinez O: Gastric mucosal cell proliferation in ethanol-induced chronic mucosal injury is related to oxidative stress and lipid peroxidation in rats. Lab Invest. 2000 Aug;80(8):1161-9. [PubMed:10950107]
  3. Kuint J, Linder N, Reichman B: Hypoxemia associated with cimetidine therapy in a newborn infant. Am J Perinatol. 1996 Jul;13(5):301-3. [PubMed:8863950]
  4. Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
3. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Trimethylamine monooxygenase activity
Specific Function
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an impor...
Gene Name
FMO3
Uniprot ID
P31513
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight
60032.975 Da
References
  1. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082]
  2. Cashman JR, Park SB, Berkman CE, Cashman LE: Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact. 1995 Apr 28;96(1):33-46. [PubMed:7720103]
  3. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Nadp binding
Specific Function
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name
FMO1
Uniprot ID
Q01740
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 1
Molecular Weight
60310.285 Da
References
  1. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698]
  2. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  4. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226]
  5. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
  2. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030]
  4. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712]
  5. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798]
  6. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855]
  7. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071]
  8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  9. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030]
  4. Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM: Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem. 1997 Jun 27;272(26):16548-54. [PubMed:9195965]
  5. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712]
  6. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798]
  7. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol. 2001 Aug;21(16):5471-7. [PubMed:11463829]
  8. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
  9. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Grundemann D, Schechinger B, Rappold GA, Schomig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998 Sep;1(5):349-51. [PubMed:10196521]
  2. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924]
  3. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645]
  4. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [PubMed:9618255]
  2. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  3. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  3. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115]
  4. Burckhardt BC, Brai S, Wallis S, Krick W, Wolff NA, Burckhardt G: Transport of cimetidine by flounder and human renal organic anion transporter 1. Am J Physiol Renal Physiol. 2003 Mar;284(3):F503-9. Epub 2002 Nov 12. [PubMed:12429554]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  3. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  5. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
  6. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115]
  7. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720]
  8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  9. Bakhiya A, Bahn A, Burckhardt G, Wolff N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13(5):249-56. [PubMed:14586168]
  10. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]
  11. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC: Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44. doi: 10.1124/jpet.110.170753. Epub 2010 Jun 2. [PubMed:20519552]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wilson A. (2016). New horizons in predictive drug metabolism and pharmacokinetics. The Royal Society of Chemistry. [ISBN:978-1-84973-828-6]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41